Business Context and Reporting Period
This Form 8-K Current Report from Madrigal Pharmaceuticals, Inc. (MDGL) covers events occurring on June 27, 2019, and was filed on July 2, 2019. The report details the outcomes of the Company's 2019 Annual Meeting of Stockholders and the appointment of a new director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and equity plan matters.
Material Changes and Corporate Actions
- Board Appointment: James M. Daly was appointed to the Board of Directors, effective June 27, 2019. The Board size was increased to eight members. Mr. Daly was elected as a Class I director with a term expiring at the 2020 Annual Meeting.
- Compensation for New Director: Mr. Daly received a stock option to purchase 20,000 shares of common stock. The option has an exercise price of $100.45 per share, a five-year term, and vests over two years subject to continued service.
- Stock Plan Amendment: Stockholders approved an amendment to the 2015 Amended Stock Plan, increasing the number of shares reserved for issuance by 500,000.
- Shareholder Voting: As of the record date (May 3, 2019), there were 15,418,364 shares outstanding. 14,760,936 shares were present or represented by proxy at the Annual Meeting.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. It notes that Mr. Daly brings over 30 years of experience in the biopharmaceutical industry, including roles at Incyte, Amgen, and GSK, which the Board believes qualifies him to serve.
Investor Verification Checklist
- Verify the impact of the 500,000 share increase in the Stock Plan on potential future dilution.
- Review the definitive Proxy Statement (filed May 15, 2019) for full details on the Stock Plan amendment and director biographies.
- Confirm the vesting schedule and exercise price ($100.45) of the options granted to the new director, James M. Daly.
- Note that the Board has determined to hold annual advisory votes on executive compensation ("Say-on-Pay") based on the results of Proposal 5.